Healthcare Services

A key trend shaping the Oncolytic Virus Therapy Market involves the Accelerating Oncolytic Virus Therapy Development Through Regulatory Approvals

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Oncolytic Virus Therapy Market During 2026–2030?

The oncolytic virus therapy market has experienced significant expansion in recent years. Its valuation is predicted to increase from $0.23 billion in 2025 to $0.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. This historical progression can be attributed to several factors: the creation of HSV- and adenovirus-based oncolytic treatments, early clinical trials targeting melanoma and breast cancer, a surge in interest from cancer research institutes, augmented government funding for virotherapy research, and strengthening collaborations between biotechnology firms and academic institutions.

The oncolytic virus therapy market is projected to experience substantial growth over the next few years. It is anticipated to expand to $0.68 billion by 2030, achieving a compound annual growth rate (CAGR) of 23.7%. This growth during the forecast period is attributable to an escalating demand for genetically engineered oncolytic viruses, their increasing adoption in lung, prostate, and brain cancers, the expansion of specialty clinics and hospitals offering virotherapy, rising investment in combination and emerging virus therapies, and the development of clinical trial infrastructure in nascent markets. Major trends expected in the forecast period include the increasing integration of AI and big data into oncolytic virus research, a greater focus on genomics and precision medicine for therapy design, broader implementation of digital platforms for clinical trial monitoring, enhanced automation in virus production and quality assurance, and the expanding use of IoT-based systems for monitoring virus storage and distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Economic Or Industry Drivers Are Impacting The Oncolytic Virus Therapy Market?

The rising occurrence of cancer cases is anticipated to propel the expansion of the oncolytic virus therapy market moving forward. Cancer describes a collection of diseases defined by the uncontrolled proliferation and spread of abnormal cells within the body. Oncolytic virus therapy provides the ability to selectively target and eliminate cancer cells, while also stimulating an immune response against the tumor, thereby offering a dual mechanism of action for effective cancer treatment. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, which represents a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer cases is a key factor driving the growth of the oncolytic virus therapy market.

How Are The Various Segments Of The Oncolytic Virus Therapy Market Categorized?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

What Trends Are Advancing Progress In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are primarily focused on obtaining regulatory approvals to accelerate the introduction of innovative therapies for cancer treatment. Regulatory approvals signify the process through which health authorities evaluate and authorize medical products, including drugs, biologics, and medical devices, for market use. For instance, in March 2024, ImmVira, a China-based biotechnology company, was granted Fast Track designation by the FDA for its oncolytic virus therapy, MVR-T3011 IT, intended for treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have experienced disease progression after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. This designation is designed to expedite the development and review process for therapies addressing serious conditions with unmet medical needs.

Which Major Firms Influence Developments In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Read the full oncolytic virus therapy market report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

What Are The Top-Performing Regions Within The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncolytic Virus Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company

Clinical Nutrition For Cancer Care Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-cancer-care-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795